RBC Capital maintains Pacira BioSciences at Sector Perform
RBC Capital reiterated its “Sector Perform” rating on Pacira BioSciences, per a Benzinga ratings-action roundup.
Story updates
02:58:00 PM UTC
SquawkNews
Pacira BioSciences Price Target Raised to $36.50/Share From $25.00 by RBC Capital